PAVMED INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.72 USD | -2.82% |
|
-7.53% | -58.25% |
| 03-27 | Transcript : PAVmed Inc., Q4 2023 Earnings Call, Mar 27, 2024 | |
| 03-25 | PAVmed Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2024 * | 5.52M 442M | Sales 2025 * | 18.36M 1.47B | Capitalization | 15.78M 1.26B |
|---|---|---|---|---|---|
| Net income 2024 * | -60M -4.8B | Net income 2025 * | -58M -4.64B | EV / Sales 2024 * | 2.86 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.86 x |
| P/E ratio 2024 * |
-0.32
x | P/E ratio 2025 * |
-0.63
x | Employees | 107 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.77% |
More Fundamentals
* Assessed data
More news
Latest transcript on PAVmed Inc.
More recommendations
More press releases
| 1 day | -2.82% | ||
| 1 week | -7.53% | ||
| Current month | -19.63% | ||
| 1 month | -16.50% | ||
| 3 months | -25.22% | ||
| 6 months | -56.57% | ||
| Current year | -58.25% |
1 week
1.71
1.93
1 month
1.712.66
Current year
1.604.29
1 year
1.609.00
3 years
1.60145.50
5 years
1.60145.50
10 years
1.60228.60
| Managers | Title | Age | Since |
|---|---|---|---|
Lishan Aklog
CEO | Chief Executive Officer | 58 | 25/06/14 |
Dennis McGrath
DFI | Director of Finance/CFO | 67 | 20/03/17 |
Suman M. Verma
CTO | Chief Tech/Sci/R&D Officer | - | 20/10/21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
James Cox
BRD | Director/Board Member | 81 | 31/12/14 |
Ronald Sparks
BRD | Director/Board Member | 69 | 31/12/14 |
Debra White
BRD | Director/Board Member | 62 | 21/04/21 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 1.72 | -2.82% | 30,854 |
| 25/04/24 | 1.77 | -4.32% | 63,436 |
| 24/04/24 | 1.85 | -1.07% | 18,531 |
| 23/04/24 | 1.87 | -0.53% | 28,419 |
| 22/04/24 | 1.88 | +1.08% | 35,936 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotes
PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates through three lines of business: Medical Devices, Diagnostics, and Digital Health. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is focused on enhanced personalized cancer care through remote patient monitoring using implantable vascular access port with wireless communication combined with an oncologist-designed remote digital healthcare platform.
Calendar
21/05/2024
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
1.72
USD
Average target price
15.38
USD
Spread / Average Target
+793.90%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -58.25% | 15.78M | |
| +8.07% | 219B | |
| +6.59% | 183B | |
| +11.26% | 133B | |
| +26.57% | 108B | |
| +13.35% | 52.02B | |
| -0.62% | 48.2B | |
| -0.93% | 40.37B | |
| +11.54% | 39.35B | |
| +26.76% | 32.03B |
- Stock Market
- Equities
- PAVM Stock
